Ascendis Pharma may be overvalued with poor growth indicators, but the 3 analysts following the company give it an average rating of buy. The analysts have set target prices ranging from $0.35 to $0.4 per share, for an average of $0.38. At today's price of $84.01, Ascendis Pharma is trading 22007.89% away from its average target price, suggesting there is an analyst belief that shares are overpriced.
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. Based in Hellerup, Denmark, the mid-cap Health Care company has 797 full time employees. Ascendis Pharma has not offered a regular dividend during the last year.
Ascendis Pharma does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at -0.03. The average P/E ratio for the Health Care sector is 24.45. Furthermore, Ascendis Pharma is likely overvalued compared to its book value, since its P/B ratio of 17.9 is higher than the sector average of 4.16.
If analysts are giving the the company a decent rating despite its hefty price point, it could be related to its strong cash flows. They might also believe that Ascendis Pharma A/S's positive margin growth trend will continue.
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (k) | $13,375 | $6,953 | $7,778 | $51,174 |
| Revenue Growth | n/a | -48.01% | 11.87% | 557.93% |
| Gross Margins | n/a | n/a | 54.7% | 76.3% |
| Gross Margins Growth | n/a | n/a | n/a | 39.49% |
| Operating Margins | -1695.1% | -4755.1% | -5808.6% | -1097.8% |
| Operating Margins Growth | n/a | -180.52% | -22.16% | 81.1% |
| Net Margins | -1630.03% | -6025.53% | -4931.56% | -1139.63% |
| Net Margins Growth | n/a | -269.66% | 18.16% | 76.89% |
| Earnings Per Share | -$4.69 | -$8.28 | -$7.0 | -$10.38 |
| EPS Growth | n/a | -76.55% | 15.46% | -48.29% |
| Diluted Shares (MM) | 47 | 51 | 55 | 57 |
| Free Cash Flow (k) | -$181,095 | -$293,100 | -$441,883 | -$510,188 |
| FCF Growth | n/a | -61.85% | -50.76% | -15.46% |
| Capital Expenditures (k) | -$5,159 | -$21,552 | -$24,234 | -$14,489 |
| LT Debt to Equity | nan | nan | nan | 1.83 |
